Stocks · News reference
QUICK SPARK: Russell 2000 Hits New Record Highs, Beats Nasdaq 100 In 2026
The Russell 2000 hits a record high as small caps outperform the Nasdaq 100, led by three companies, including AN2 Therapeutics.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.
Aehr Test Systems Insider Sells $847,000 Worth of Stock
Vernon Rogers, Executive VP of Sales & Marketing at Aehr Test Systems, sold 5,994 shares worth $847,000 at $141.34 per share. The sale represents only a 3% reduction in his direct holdings, with Rogers retaining 186,232 shares valued at $27.1 million. The transaction occurred after the stock surged 695% over the past 12 months, and analysts view this as routine profit-taking rather than a sign of concern about the company's future.
Shares of semiconductor and chip companies are trading lower, possibly after Federal Reserve Chairman Warsh's comments on inflation and prices raised rate-hike concerns. The sector may be facing pressure from peer Marvell Technology, as the company pulls back after its FY28 guidance may have failed to meet investor expectations.
AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.